COMMUNIQUÉS West-GlobeNewswire

LUKE Awarded Top Workplaces 2024 Honor

30/09/2024 - 14:00

ROCKLEDGE, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the U.S. Government, is proud to announce that it has been awarded a Top Workplaces 2024 [...]

Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities

30/09/2024 - 14:00

DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced [...]

COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis

30/09/2024 - 14:00

CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for Primary Biliary Cholangitis CNP-104 was [...]

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

30/09/2024 - 13:35

MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

30/09/2024 - 13:30

- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the U.S. for BBP-418 in [...]

BrightSpring Health Services, Inc. Welcomes Dr. Steve Miller to Board of Directors

30/09/2024 - 13:30

LOUISVILLE, Ky., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations [...]

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

30/09/2024 - 13:30

IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program with U.S. Food and [...]

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

30/09/2024 - 13:30

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024

30/09/2024 - 13:30

Clinical data demonstrated treatment with AGA2118 resulted in dose-dependent increases in bone mineral density WOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage [...]

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

30/09/2024 - 13:30

Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study expected to begin in H1 2025 in [...]

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

30/09/2024 - 13:30

Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™ Purchase price of US$9.51 represents [...]

Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024

30/09/2024 - 13:30

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, [...]

Novellia and University of Alabama at Birmingham Study Examines Biomarker Testing Practices for Non-Small Cell Lung Cancer

30/09/2024 - 13:05

- Research study presented at the 2024 ASCO Quality Care Symposium uses Novellia's AI-enabled technology and personal health record platform to unlock insights that can inform patient care - NEW YORK, Sept. 30, 2024 ( [...]

Kraig Biocraft Laboratories Leverages New Production Center for Largest Ever Batch of Spider Silk Parental Lines

30/09/2024 - 13:05

ANN ARBOR, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of commercially viable spider silk, today proudly announces the [...]

Novo Nordisk A/S – Share repurchase programme

30/09/2024 - 13:02

Bagsværd, Denmark, 30 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Prime Medicine Unveils Strategically Focused Pipeline

30/09/2024 - 13:01

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical [...]

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

30/09/2024 - 13:00

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial [...]

Hydreight Announces Normal Course Issuer Bid

30/09/2024 - 13:00

LAS VEGAS and VANCOUVER, British Columbia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6) (the “ Company ”), a fast-growing mobile clinical network and medical [...]

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

30/09/2024 - 13:00

GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ( [...]